GlaxoSmithKline PLC Directorate Change (5160U)
April 06 2021 - 9:30AM
UK Regulatory
TIDMGSK
RNS Number : 5160U
GlaxoSmithKline PLC
06 April 2021
Issued: 6 April 2021, London UK
GSK announces Dr Anne Beal to join the Board as Non-Executive
Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne
Beal will join the Board of the Company as a Non-Executive Director
with effect from 6 May 2021.
On joining the Board, Dr Beal will become a member of the
Corporate Responsibility Committee (the 'Committee') which provides
important oversight of the Company's Trust agenda including
policies towards access to medicines, global health, inclusion and
diversity and environmental sustainability. Dr Beal will succeed
Lynn Elsenhans as Chair of the Committee after the 2022 Annual
General Meeting. Ms Elsenhans has agreed to remain on the Board for
a further year to facilitate an orderly transition to Dr Beal's
leadership of the Committee.
Dr Beal will bring to GSK extensive healthcare experience as a
physician and entrepreneur combined with a passion for patient
advocacy. She is a recognised health policy expert in the
development of global and national programmes for improving
healthcare access for all patient groups and in ensuring the voice
of patients is reflected in research programmes.
Commenting on the changes, Sir Jonathan Symonds, Chairman of GSK
said: "I am delighted to welcome Anne to GSK. Acting responsibly is
an integral part of how successful modern businesses deliver for a
wide range of stakeholders including investors. That's why the work
of the Corporate Responsibility Committee is critical to the
success of GSK. Anne's expertise and experience will be a valuable
addition to GSK and to the leadership of the Committee. I would
like to thank Lynn for her service to the Company over the last
nine years and to agreeing to stay on to ensure a smooth transition
to Anne."
Dr Beal is founder and CEO of AbsoluteJOI Skincare and a member
of the Board of AcademyHealth. Prior to her current roles, Dr Beal
spent six years at Harvard Medical School and Massachusetts General
Hospital, where she was an instructor in paediatrics and has also
held leadership roles at the Commonwealth Fund and the Aetna
Foundation. In addition, Dr Beal was previously Deputy Executive
Director and Chief Engagement Officer for The Patient-Centered
Outcomes Research Institute in the U.S. and Chief Patient Officer
and Global Head of Patient Solutions at Sanofi.
She holds a B.A. from Brown University, an M.D. from Cornell
University Medical College, and an M.P.H. from Columbia
University.
Notes
1. The appointment of Dr Anne Beal was made by the Board on
the recommendation of the Nominations & Corporate Governance
Committee.
2. The Board has determined that Dr Beal will be an independent
Non-Executive Director on appointment in accordance with
the UK Corporate Governance Code.
3. Dr Beal will receive the standard basic fee for a Non-Executive
Director of GBP95,000 per annum. She will receive a further
payment of GBP40,000 per annum when she succeeds Ms Elsenhans
as Chair of the Corporate Responsibility Committee.
Dr Beal will be required to invest at least 25% of her fees
in GSK shares that should be held until her retirement from
the Board.
4. Membership of other Committees will be determined in due
course.
5. Dr Beal does not have a service contract. She has a letter
of appointment which may be viewed by contacting the Company
Secretary at the Company's registered office.
6. There are no additional details to disclose in respect of
Dr Beal's appointment under Listing Rule 9.6.13R.
7. From 6 May 2021 the Board of GSK will comprise:
Sir Jonathan Symonds Non-Executive Chairman
Emma Walmsley Chief Executive Officer
Iain Mackay Chief Financial Officer
Dr Hal Barron Chief Scientific Officer and President,
Vindi Banga R&D
Charles Bancroft Senior Independent Non-Executive Director
Dr Anne Beal Independent Non-Executive Director
Dr Vivienne Cox Independent Non-Executive Director
Lynn Elsenhans Independent Non-Executive Director
Dr Jesse Goodman Independent Non-Executive Director
Dr Laurie Glimcher Independent Non-Executive Director
Urs Rohner Independent Non-Executive Director
Independent Non-Executive Director
As previously announced, Charles Bancroft has succeeded
Judy Lewent as Chair of the Audit & Risk Committee following
approval of GSK's 2020 Annual Report. Judy will not stand
for re-election to the Board at GSK's Annual General Meeting
on 5 May 2021.
Lynn Elsenhans will stand for re-election at the AGM and
remain on the Board for a further year to facilitate a smooth
handover to Dr Beal.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Madeleine Breckon +44 (0) 7880 (London)
040 329
Kristen Neese +1 804 217 8147 (Philadelphia)
Analyst/Investor James Dodwell +44 (0) 20 8047 (London)
enquiries: 2406
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
Mick Readey +44 (0) 7990 (London)
339653
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZZGGDMVRGMZM
(END) Dow Jones Newswires
April 06, 2021 09:30 ET (13:30 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024